Cargando…

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors

Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKI) are a therapeutic option as second-line therapy in non-small-cell lung carcinoma (NSCLC), regardless of the EGFR gene status. Identifying patients with early progression during EGFR-TKI treatment will help clinicians to choose th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rozensztajn, Nathalie, Ruppert, Anne-Marie, Lavole, Armelle, Leprieur, Etienne Giroux, Duruisseaux, Michael, Vieira, Thibault, Rabbe, Nathalie, Lacave, Roger, Antoine, Martine, Cadranel, Jacques, Wislez, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Ltd. 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930390/ https://www.ncbi.nlm.nih.gov/pubmed/24408092 http://dx.doi.org/10.1002/cam4.180

Ejemplares similares

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
por: Duruisseaux, Michaël, et al.
Publicado: (2016)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
por: Cadranel, Jacques, et al.
Publicado: (2019)

Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study
por: Decavèle, Maxens, et al.
Publicado: (2022)

Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus
por: Boussaud, Véronique, et al.
Publicado: (2003)

Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study
por: Ezzedine, Rémy, et al.
Publicado: (2023)

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
por: Costantini, Adrien, et al.
Publicado: (2018)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
por: Girard, N., et al.
Publicado: (2020)

Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
por: Bertin, Lise, et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab
por: Dumenil, Coraline, et al.
Publicado: (2018)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
por: Bouchez, Clémentine, et al.
Publicado: (2020)

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung
por: Saffroy, Raphaël, et al.
Publicado: (2017)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy
por: Arrouss, Issam, et al.
Publicado: (2013)

Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies
por: Giroux Leprieur, Etienne, et al.
Publicado: (2018)

Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR
por: Léonce, Camille, et al.
Publicado: (2023)

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients
por: Gounant, Valérie, et al.
Publicado: (2021)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report
por: Magdelaine, Pierre, et al.
Publicado: (2022)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2021)

Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
por: Giroux-Leprieur, Etienne, et al.
Publicado: (2018)

Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer
por: Giroux Leprieur, Etienne, et al.
Publicado: (2017)

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2022)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Successful pulmonary arterial embolization followed by curative surgery for a lepidic predominant lung adenocarcinoma with severe hypoxemia
por: Sebane, Louise, et al.
Publicado: (2018)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Augmentation des délais de prise charge du cancer du poumon pendant la pandémie COVID-19 : expérience d’un centre de diagnostic rapide ambulatoire
por: Wang, P., et al.
Publicado: (2022)

Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
por: Bilger, Geoffroy, et al.
Publicado: (2022)

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank
por: Stücker, Isabelle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k22rqopkhmk52a1u7abs28micg